Nephrocare Health Services Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹266Cr
- +21.5% YoY
- +2.3% QoQ
- Net profit
- ₹30Cr
- +20% YoY
- −6.2% QoQ
- Margin
- 19%
- −4 pp YoY
- −4 pp QoQ
Guidance rank: #30 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
What the Q4 FY26 call signalled
2 of 3 strong
The short version
FY26 revenue grew by 32.2% YoY to INR 998.8 crores, driven by higher treatment volumes, clinic utilization, and increased revenue per treatment (RPT). NephroPlus expects a medium-term CAGR growth of 15% to 20% over the next 3-4 years driven by three growth levers: same-clinic growth, new clinic rollout in existing geographies, and new geography/large acquisitions/PPPs.
From Nephrocare Health Services Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY26 revenue grew by 32.2% YoY to INR 998.8 crores, driven by higher treatment volumes, clinic utilization, and increased revenue per treatment (RPT).
- Treatment volumes increased 16.6% YoY; active guests up 11.8%.
- RPT rose 13.3%, boosted by international market mix increase (32% to 42%), favorable forex, and a 58% price hike in the Philippines.
- India plans to add 40-50 new clinics annually; Philippines targeting 12-15 clinics/year.
- Clinic expansions focus on treatment volume growth, as per-machine capacity is fixed; new clinics needed for volume increase.
- Price hikes are infrequent and stepwise; no significant increases expected next year; growth primarily volume-driven.
2 more points from Nephrocare Health Services Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Nephrocare Health Services Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY 2026 capex was INR 165 crores, split evenly between India, Philippines, and a bit in Uzbekistan.
- Capex per bed: India ~ INR 10-11 lakhs, Philippines ~ INR 40-45 lakhs.
- Payback periods: India ~3.5-4 years, Philippines ~1-1.5 years.
- Planned clinic additions: India 40-50 new clinics/year, Philippines 12-15 new clinics/year (excluding large PPPs or big acquisitions).
- Future investments include expanding Philippines support areas like supply chain management and business development.
- Repair and maintenance expenses now flow through operating expenses due to accounting changes.
- Exploring Public-Private Partnership (PPP) models in Philippines and India as a strategic growth lever.
2 more points from Nephrocare Health Services Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Nephrocare Health Services Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Nephrocare Health Services Ltd — Quarterly revenue & net profit
Nephrocare Health Services Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 266 | 219 | +21.5% | 260 | +2.3% |
| Operating profit (EBITDA) | 51 | 51 | 0% | 61 | -16.4% |
| Operating margin | 19% | 23% | -4 pp | 23% | -4 pp |
| Profit before tax | 33 | 30 | +10% | 36 | -8.3% |
| Net profit (PAT) | 30 | 25 | +20% | 32 | -6.2% |
| EPS (₹) | 3.03 | 23.91 | -87.3% | 3.21 | -5.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹303 Cr, net profit ₹34 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Nephrocare Health Services's management said in earlier quarters
Others in Healthcare Services this season
- Suven Life Sciences (Q4 FY26)
The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su
- Invicta Diagnostic (Q4 FY26)
Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnostic's Q4 FY26 earnings…
- KMC Speciality (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
- Star Imaging (Q4 FY26)
Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Nephrocare Health Services Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Nephrocare Health Services Ltd Q4 FY26 results?
FY26 revenue grew by 32.2% YoY to INR 998.8 crores, driven by higher treatment volumes, clinic utilization, and increased revenue per treatment (RPT). NephroPlus expects a medium-term CAGR growth of 15% to 20% over the next 3-4 years driven by three growth levers: same-clinic growth, new clinic rollout in existing geographies, and new geography/large acquisitions/PPPs.
What is Nephrocare Health Services Ltd share price analysis?
Nephrocare Health Services Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 82.3 with a market cap of ₹7,006 Cr. Investors should review the full earnings analysis for detailed insights.
Is Nephrocare Health Services Ltd planning capital expenditure?
FY 2026 capex was INR 165 crores, split evenly between India, Philippines, and a bit in Uzbekistan.
Keep Nephrocare Health Services Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
